FindTrial
Sign In

J3R-MC-YDAO - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight (ENLIGHTEN-3) Intervention-Specific Appendices (ISAs): J3R-MC-YSA1: Participants unable or unwilling to use positive airway pressure therapy J3R-MC-YSA2: Participants treated with positive airway pressure therapy

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523769-11-00
Enrollment
85
Registered
2026-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Obesity, Sleep Apnea, Obstructive

Brief summary

Percent Change from Baseline in Body Weight

Interventions

DRUGEloralintide
DRUGPlacebo to match LY

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Percent Change from Baseline in Body Weight—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 21, 2026